All In Biotech

Drug Trial Radar · NCT05709171

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 17, 2023

Primary completion

Jan 1, 2025

Study completion Jan 1, 2026

Sponsor

Lead sponsor
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective clinical trial investigating combined, dual 18F-FDG PET/CT and 64Cu-DOTATATE PET/CT imaging of patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN)

Conditions

  • GEP-NET
  • Neuroendocrine Tumors
  • Neuroendocrine Carcinoma
  • Neuroendocrine Carcinoma Metastatic

Interventions

  • 18F-FDGDrug

    PET/CT scan approximately 60 min after injection of 18F-FDG

  • 64Cu-DotatateDrug

    PET/CT scan approximately 60 min after injection of 64Cu-Dotatate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: 12 months after last-patients-last-visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.